`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioner
`
`v.
`
`MERCK PATENTGESELLSCHAFT,
`Patent Owner.
`
`U.S. Patent No. 8,673,921
`Issue Date: March 18, 2014
`Title: POLYMORPHIC FORMS OF
`1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4-
`(2-CARBAMOYLBENZOFURAN-5-YL)
`PIPERAZINE HYDROCHLORIDE
`
`Inter Partes Review No.: Unassigned
`
`DECLARATION OF GABRIELA GURAU, PH.D.
`
`Argentum EX1039
`
`Page 1
`
`
`
`
`
`I, Gabriela Gurau, Ph.D., do hereby declare and state as follows:
`
`1.
`
`I am currently CEO and Co-owner of 525 Solutions, Inc. After
`
`receiving my Ph.D. degree in Chemistry from The University of Alabama, I accepted
`
`a position as a Postdoctoral Research Fellow at QUILL (Queen's University Ionic
`
`Liquid Laboratories) in Belfast, Northern Ireland, an industrial consortium with
`
`members from all sectors of the chemical industry. In 2009, I returned to Alabama
`
`where I held the positions of postdoc at The University of Alabama and Chief
`
`Technical Officer at 525 Solutions. In 2015, I accepted a position at McGill
`
`University, Montreal, Canada as an Academic Associate in Green Chemistry,
`
`managing the $10M Canada Excellence Research Chair program. I returned to 525
`
`Solutions in 2017.
`
`2.
`
`I am being compensated for my work at a rate of $150 per hour. My
`
`compensation is not dependent on and in no way affects the substance of my
`
`statements in this Declaration. I have no financial interest in the outcome of this
`
`proceeding.
`
`3.
`
`I have personal knowledge of the experiments performed in the
`
`laboratory notebook pages marked as Exhibit 1034. I hereby declare that Exhibit
`
`1034 is a true and correct copy of the laboratory notebook that I used when I
`
`performed the experiments under the supervision and direction of Dr. Robin D.
`
`Rogers, Ph.D. between October 23, 2017 and December 12, 2017.
`
`1
`
`Page 2
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Date: December 15, 2017
`
`
`
`
`
`
`RESPECTFULLY SUBMITTED,
`
`
`
`
`
`Gabriela Gurau, Ph.D.
`
`2
`
`Page 3
`
`